research Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
Search
for
Sort by
Research
450-480 / 1000+ results
research Combining 308-monochromatic excimer phototherapy with monthly IM triamcinolone acetonide for the treatment of resistant alopecia totalis
The combination therapy was effective and well-tolerated, especially in young patients.
research 572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma
Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib
research 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy
Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
research Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma
The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
research BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the AIRE gene mutation treated with ruxolitinib
Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
research Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab
research Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
research Successful hair regrowth in an acute diffuse form of alopecia areata during oral tacrolimus treatment in a patient with rheumatoid arthritis
Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
research THU0301 A Phase II Trial of Retinoids on Lupus Nephritis in A Single Center
Retinoids may help treat lupus nephritis and reduce steroid use.
research Myeloproliferative disorder associated with alopecia universalis
Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.
research Combination Therapy with 308-nm Excimer Laser, Compound Glycyrrhizin, and Tacrolimus for Pediatric Facial and Cervical Vitiligo
The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
research ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
research Complete remission of alopecia areata under treatment of chronic hand eczema with alitretinoin
Alitretinoin may help treat alopecia areata.
research 586 Increase in CD8+ effector memory cells re-expressing CD45RA (TEMRA) reflects disease activity and enables early prediction of therapeutic outcome in rapidly progressive alopecia areata
Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
research [Successful treatment of "steroid-immunosuppressant resistant" polymyositis with immunoadsorption].
Immunoadsorption successfully treated a man's resistant polymyositis.
research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
research Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
Upadacitinib effectively treats psoriasiform eczema and some related conditions.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients
Adalimumab improved folliculitis decalvans in most patients.
research Anais do II Congresso Nacional Acadêmico de Dermatologia
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
research LB1681 Risk of merkel cell carcinoma progression after treatment discontinuation in patients with an objective response to anti-PD-(L)1 immunotherapy
Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.